190 related articles for article (PubMed ID: 31701524)
1. Proposed Therapeutic Range of Treosulfan in Reduced Toxicity Pediatric Allogeneic Hematopoietic Stem Cell Transplant Conditioning: Results From a Prospective Trial.
Chiesa R; Standing JF; Winter R; Nademi Z; Chu J; Pinner D; Kloprogge F; McLellen S; Amrolia PJ; Rao K; Lucchini G; Silva J; Ciocarlie O; Lazareva A; Gennery AR; Doncheva B; Cant AJ; Hambleton S; Flood T; Rogerson E; Devine K; Prunty H; Heales S; Veys P; Slatter M
Clin Pharmacol Ther; 2020 Aug; 108(2):264-273. PubMed ID: 31701524
[TBL] [Abstract][Full Text] [Related]
2. Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients.
Baronciani D; Rambaldi A; Iori AP; Di Bartolomeo P; Pilo F; Pettinau M; Depau C; Mico C; Santarone S; Angelucci E
Am J Hematol; 2008 Sep; 83(9):717-20. PubMed ID: 18626885
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic stem cell transplantation.
Kletzel M; Jacobsohn D; Duerst R
Biol Blood Marrow Transplant; 2006 Apr; 12(4):472-9. PubMed ID: 16545731
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Pharmacodynamics of Treosulfan in Patients With Thalassemia Major Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Mohanan E; Panetta JC; Lakshmi KM; Edison ES; Korula A; Na F; Abraham A; Viswabandya A; George B; Mathews V; Srivastava A; Balasubramanian P
Clin Pharmacol Ther; 2018 Sep; 104(3):575-583. PubMed ID: 29247522
[TBL] [Abstract][Full Text] [Related]
5. Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation.
Wall DA; Chan KW; Nieder ML; Hayashi RJ; Yeager AM; Kadota R; Przepiorka D; Mezzi K; Kletzel M;
Pediatr Blood Cancer; 2010 Feb; 54(2):291-8. PubMed ID: 19743300
[TBL] [Abstract][Full Text] [Related]
6. Engraftment kinetics and hematopoietic chimerism after reduced-intensity conditioning with fludarabine and treosulfan before allogeneic stem cell transplantation.
Blau IW; Schmidt-Hieber M; Leschinger N; Göldner H; Knauf W; Hopfenmüller W; Thiel E; Blau O
Ann Hematol; 2007 Aug; 86(8):583-9. PubMed ID: 17468869
[TBL] [Abstract][Full Text] [Related]
7. Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium.
Nemecek ER; Hilger RA; Adams A; Shaw BE; Kiefer D; Le-Rademacher J; Levine JE; Yanik G; Leung W; Talano JA; Haut P; Delgado D; Kapoor N; Petrovic A; Adams R; Hanna R; Rangarajan H; Dalal J; Chewning J; Verneris MR; Epstein S; Burroughs L; Perez-Albuerne ED; Pulsipher MA; Delaney C
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1651-1656. PubMed ID: 29753157
[TBL] [Abstract][Full Text] [Related]
8. Outcomes from hematopoietic stem cell transplantation following treosulfan-based conditioning: A clinical and pharmacokinetic analysis.
Rosser SPA; Brewer A; Gabriel M; Wong M; Chung J; McLachlan AJ; Nath CE; Keogh SJ; Shaw PJ
Pediatr Transplant; 2024 Jun; 28(4):e14780. PubMed ID: 38766999
[TBL] [Abstract][Full Text] [Related]
9. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes.
Russell JA; Tran HT; Quinlan D; Chaudhry A; Duggan P; Brown C; Stewart D; Ruether JD; Morris D; Glick S; Gyonyor E; Andersson BS
Biol Blood Marrow Transplant; 2002; 8(9):468-76. PubMed ID: 12374451
[TBL] [Abstract][Full Text] [Related]
10. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation.
Bartelink IH; Bredius RG; Ververs TT; Raphael MF; van Kesteren C; Bierings M; Rademaker CM; den Hartigh J; Uiterwaal CS; Zwaveling J; Boelens JJ
Biol Blood Marrow Transplant; 2008 Jan; 14(1):88-98. PubMed ID: 18158965
[TBL] [Abstract][Full Text] [Related]
11. Population pharmacokinetics of treosulfan in paediatric patients undergoing hematopoietic stem cell transplantation.
van der Stoep MYEC; Zwaveling J; Bertaina A; Locatelli F; Guchelaar HJ; Lankester AC; Moes DJAR
Br J Clin Pharmacol; 2019 Sep; 85(9):2033-2044. PubMed ID: 31144349
[TBL] [Abstract][Full Text] [Related]
12. Comparison of Different Conditioning Regimens of Haploidentical Hematopoietic Stem Cell Transplant in Patients With Acute Myeloid Leukemia.
Jiang Y; Fang X; Sui X; Liu X; Li Y; Wang X; Xu H; Zhang L; Wang X
Exp Clin Transplant; 2018 Dec; 16(6):736-744. PubMed ID: 29790457
[TBL] [Abstract][Full Text] [Related]
13. Acute toxicity and outcome among pediatric allogeneic hematopoietic transplant patients conditioned with treosulfan-based regimens.
Huttunen P; Taskinen M; Vettenranta K
Pediatr Hematol Oncol; 2020 Aug; 37(5):355-364. PubMed ID: 32166994
[TBL] [Abstract][Full Text] [Related]
14. The importance of therapeutic drug monitoring (TDM) for parenteral busulfan dosing in conditioning regimen for hematopoietic stem cell transplantation (HSCT) in children.
Tesfaye H; Branova R; Klapkova E; Prusa R; Janeckova D; Riha P; Sedlacek P; Keslova P; Malis J
Ann Transplant; 2014 May; 19():214-24. PubMed ID: 24811685
[TBL] [Abstract][Full Text] [Related]
15. Low incidence and severity of oral mucositis in allogeneic stem cell transplantation after conditioning with treosulfan and fludarabine.
Heli U; Eeva J; Anne N; Tapani R; Liisa V
Eur J Haematol; 2012 Jan; 88(1):87-8. PubMed ID: 22103782
[No Abstract] [Full Text] [Related]
16. High-dose treosulfan in conditioning prior to hematopoietic stem cell transplantation.
Główka FK; Romański M; Wachowiak J
Expert Opin Investig Drugs; 2010 Oct; 19(10):1275-95. PubMed ID: 20836619
[TBL] [Abstract][Full Text] [Related]
17. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2.
Chae YS; Sohn SK; Kim JG; Cho YY; Moon JH; Shin HJ; Chung JS; Cho GJ; Yang DH; Lee JJ; Kim YK; Kim HJ
Bone Marrow Transplant; 2007 Sep; 40(6):541-7. PubMed ID: 17637692
[TBL] [Abstract][Full Text] [Related]
18. Survival Advantage and Comparable Toxicity in Reduced-Toxicity Treosulfan-Based versus Reduced-Intensity Busulfan-Based Conditioning Regimen in Myelodysplastic Syndrome and Acute Myeloid Leukemia Patients after Allogeneic Hematopoietic Cell Transplantation.
Sakellari I; Mallouri D; Gavriilaki E; Batsis I; Kaliou M; Constantinou V; Papalexandri A; Lalayanni C; Vadikolia C; Athanasiadou A; Yannaki E; Sotiropoulos D; Smias C; Anagnostopoulos A
Biol Blood Marrow Transplant; 2017 Mar; 23(3):445-451. PubMed ID: 27914967
[TBL] [Abstract][Full Text] [Related]
19. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.
Beelen DW; Trenschel R; Stelljes M; Groth C; Masszi T; Reményi P; Wagner-Drouet EM; Hauptrock B; Dreger P; Luft T; Bethge W; Vogel W; Ciceri F; Peccatori J; Stölzel F; Schetelig J; Junghanß C; Grosse-Thie C; Michallet M; Labussiere-Wallet H; Schaefer-Eckart K; Dressler S; Grigoleit GU; Mielke S; Scheid C; Holtick U; Patriarca F; Medeot M; Rambaldi A; Micò MC; Niederwieser D; Franke GN; Hilgendorf I; Winkelmann NR; Russo D; Socié G; Peffault de Latour R; Holler E; Wolff D; Glass B; Casper J; Wulf G; Menzel H; Basara N; Bieniaszewska M; Stuhler G; Verbeek M; Grass S; Iori AP; Finke J; Benedetti F; Pichlmeier U; Hemmelmann C; Tribanek M; Klein A; Mylius HA; Baumgart J; Dzierzak-Mietla M; Markiewicz M
Lancet Haematol; 2020 Jan; 7(1):e28-e39. PubMed ID: 31606445
[TBL] [Abstract][Full Text] [Related]
20. Impact of Treosulfan Exposure on Early and Long-Term Clinical Outcomes in Pediatric Allogeneic Hematopoietic Stem Cell Transplantation Recipients: A Prospective Multicenter Study.
van der Stoep MYEC; Bertaina A; Moes DJAR; Algeri M; Bredius RGM; Smiers FJW; Berghuis D; Buddingh EP; Mohseny AB; Guchelaar HJ; Locatelli F; Zwaveling J; Lankester AC
Transplant Cell Ther; 2022 Feb; 28(2):99.e1-99.e7. PubMed ID: 34607071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
